BONE BIOLOGICS CORPORATION: 10-Q filed 2014-03-17
What BONE BIOLOGICS CORPORATION reported in its quarterly report filed 2014-03-17 (fiscal Q1 2014): 13 published measures, 43 facts as tagged in accession 0001493152-14-000758.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-03-17
- Fiscal period
- fiscal Q1 2014
- Accession
- 0001493152-14-000758 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BONE BIOLOGICS CORPORATION filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-01-31 | 94 | USD | |
| At 2013-10-31 | 380 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-01-31 | 41,878 | USD | |
| At 2013-10-31 | 40,185 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-01-31 | -41,784 | USD | |
| At 2013-10-31 | -39,805 | USD | |
| At 2012-10-31 | -34,599 | USD | |
| At 2011-10-31 | -28,968 | USD | |
| At 2010-10-31 | -24,048 | USD | |
| At 2009-10-31 | -20,451 | USD | |
| At 2008-10-31 | -10,166 | USD | |
| At 2007-10-31 | -9,723 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-01-31 | 94 | USD | |
| At 2013-10-31 | 380 | USD | |
| At 2013-01-31 | 470 | USD | |
| At 2012-10-31 | 500 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-11-01 to 2014-01-31 | -1,979 | USD | 92 |
| 2007-10-19 to 2014-01-31 | -66,784 | USD | 2297 |
| 2012-11-01 to 2013-10-31 | -5,206 | USD | 365 |
| 2012-11-01 to 2013-01-31 | -1,618 | USD | 92 |
| 2011-11-01 to 2012-10-31 | -5,631 | USD | 366 |
| 2010-11-01 to 2011-10-31 | -4,920 | USD | 365 |
| 2009-11-01 to 2010-10-31 | -3,597 | USD | 365 |
| 2008-11-01 to 2009-10-31 | -10,285 | USD | 365 |
| 2007-11-01 to 2008-10-31 | -13,343 | USD | 366 |
| 2007-10-19 to 2007-10-31 | -21,823 | USD | 13 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-11-01 to 2014-01-31 | -1,535 | USD | 92 |
| 2007-10-19 to 2014-01-31 | -62,756 | USD | 2297 |
| 2012-11-01 to 2013-01-31 | -30 | USD | 92 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-11-01 to 2014-01-31 | 1,249 | USD | 92 |
| 2007-10-19 to 2014-01-31 | 62,850 | USD | 2297 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-01-31 | 66,784 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2007-10-19 to 2014-01-31 | 15 | USD | 2297 |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-11-01 to 2014-01-31 | 1,979 | USD | 92 |
| 2007-10-19 to 2014-01-31 | 65,384 | USD | 2297 |
| 2012-11-01 to 2013-01-31 | 1,618 | USD | 92 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-01-31 | 5,000,000 | shares | |
| At 2013-10-31 | 5,000,000 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-01-31 | 20,000 | USD | |
| At 2013-10-31 | 20,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-11-01 to 2014-01-31 | -1,979 | USD | 92 |
| 2007-10-19 to 2014-01-31 | -65,384 | USD | 2297 |
| 2012-11-01 to 2013-01-31 | -1,618 | USD | 92 |
Inspect the source
- Entity
- BONE BIOLOGICS CORPORATION / CIK 0001419554
- Captured
- 2026-09-20T08:02:52.100Z
- SEC response SHA-256
7c2684db7febb4ea6b03577e138dc91ed20e12534f1d96c178894d4b68a7b815
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001419554.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))